EUVIMEDEUVIMED entdecken
Open Access

Synthesis and in vivo studies of metformin analogues for management of impaired metabolic syndrome in pancreatic ductal adenocarcinoma

Farid M Sroor iD, Wahid M Basyouni, Mohamed K El-Ashrey, Eman A Younis, Hanan F Aly

Future Medicinal Chemistry · 2026

DOI: 10.1080/17568919.2025.2605013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2026. Verfasst von Farid M Sroor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo, Egypt. Hauptthemen laut MEDLINE: Metformin, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Antineoplastic Agents. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal cancer that remains incurable because it is often detected at an advanced stage, making treatment difficult. MARTIALS AND METHODS: The reaction of free metformin (5) with isothiocyanate derivatives (6-9) and the or with 4-toluenesulfonyl isocyanate (10) afforded the targeted metformin analogues (11-15). The in vitro anticancer impact of these compounds was assessed using cell lines of BJ1, PACA2, and HePG2. RESULTS: Compound 13 had significant cytotoxic effects against PACA2 and HePG2 with mortality 88.30% and 71.20%, respectively. In a chronic study, the body weights of male rats receiving 13 at a dose of 50 mg/kg for 12 consecutive weeks showed an insignificant difference in the percentage change in body weight. Histopathological examination of the pancreas and liver with 13 exhibited normal histological structure of exocrine and endocrine parts. Additionally, normal cardiac myocytes were observed in the heart of rats treated with 13. CONCLUSIONS: It can be inferred that the daily administration of 50 mg/kg of compound 13 over a duration of 12 weeks did not elicit any substantial alterations in body weight, biochemical, hematological, or histopathological parameters, while concurrently exhibiting pronounced anticancer efficacy against pancreatic ductal adenocarcinoma (PDAC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic AgentsMetabolic SyndromeAnimalsHumansRatsMaleCell ProliferationCell Line, TumorDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Liver functionblood picturehistopathological investigationmetforminpancreatitisrenal function

Substanzen

MetforminAntineoplastic Agents

Autor:innen und Institutionen

  • Organometallic and Organometalloid Chemistry Department, National Research Centre, Cairo, Egypt.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University,Cairo, Egypt.
  • Department of Therapeutic Chemistry, National Research Centre, Cairo, Egypt.

ORCID-Profile: Farid M Sroor

Förderung

  • National Research Centre

Zitieren

APA

Sroor, F. M., Basyouni, W. M., El-Ashrey, M. K., Younis, E. A., & Aly, H. F. (2026). Synthesis and in vivo studies of metformin analogues for management of impaired metabolic syndrome in pancreatic ductal adenocarcinoma. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2025.2605013

Vancouver

Sroor FM, Basyouni WM, El-Ashrey MK, Younis EA, Aly HF. Synthesis and in vivo studies of metformin analogues for management of impaired metabolic syndrome in pancreatic ductal adenocarcinoma. Future Medicinal Chemistry. 2026. doi:10.1080/17568919.2025.2605013

BibTeX
@article{Sroor2026,
  author = {Sroor, Farid M and Basyouni, Wahid M and El-Ashrey, Mohamed K and Younis, Eman A and Aly, Hanan F},
  title = {Synthesis and in vivo studies of metformin analogues for management of impaired metabolic syndrome in pancreatic ductal adenocarcinoma},
  journal = {Future Medicinal Chemistry},
  year = {2026},
  doi = {10.1080/17568919.2025.2605013}
}
Kostenlos starten →